EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 4.0

Improvement of Intranasal Drug Delivery with Intravail® Alkylsaccharide Excipient as a Mucosal Absorption Enhancer Aiding in the Treatment of Conditions of the Central Nervous System

Adrian L Rabinowicz, Enrique Carrazana, Edward T Maggio

Drugs in R&D · 2021-12 · 21 (4) · 361-369

DOI: 10.1007/s40268-021-00360-5 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Drugs in R&D, online erschienen am 25.08.2021. Verfasst von Adrian L Rabinowicz und 2 weiteren Autor:innen. Beteiligte Einrichtung: Neurelis, Inc., San Diego, CA, USA. arabinowicz@neurelis.com. Hauptthemen laut MEDLINE: Excipients, Pharmaceutical Preparations. Die Arbeit wurde bisher 47-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Neurelis, Inc..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Intranasal drug administration is a commonly used route for therapeutic formulations, but there may be challenges associated with a lack of absorption and bioavailability, as well as damage to mucosal tissue. To address these issues, potential absorption enhancers that are generally nonirritating to nasal mucosal tissue have been investigated as excipients in intranasal formulations. Among those studied are alkylsaccharides, which are composed of sugars covalently coupled to at least one alkyl chain. Alkylsaccharides have been shown to be nontoxic and have been used in food products as emulsifiers. In clinical trials, alkylsaccharide excipients have demonstrated substantially increased absorption of therapeutic agents across mucosal membranes and have been shown to be applicable to a wide range of types of molecules and molecular weights. Because they are water and oil soluble, alkylsaccharide excipients can be used in formulations with both hydrophilic and hydrophobic drugs. They are also effective in safely stabilizing protein therapeutics. An example of an alkylsaccharide excipient is dodecyl maltoside (Intravail®; 511 Da, stable long term when stored cold), which provides absorption enhancement by paracellular and transcellular routes. Dodecyl maltoside has been shown to be generally nonirritating to the nose and to promote systemic bioavailability. Dodecyl maltoside is used in US Food and Drug Administration-approved intranasal formulations of sumatriptan for migraine headaches and diazepam nasal spray for patients with epilepsy with acute seizure clusters. Nasal sprays can offer an easy and efficient route to deliver drugs. The nose can absorb drugs into the bloodstream quickly, and sprays require less patient training than injection or rectal treatments. However, the nasal cavity is small, and the spray must be concentrated and easily absorbed. Alkylsaccharides may enhance absorption in the nose. They have a good safety profile and are used in foods. Intravail® alkylsaccharides include dodecyl maltoside and tetradecyl maltoside. Nasal medications with dodecyl maltoside had drug concentrations and safety similar to injectable forms. Dodecyl maltoside is used in US Food and Drug Administration-approved nasal sprays for migraine (sumatriptan [Tosymra®]) and seizure clusters (diazepam [Valtoco®]). Dodecyl maltoside is also being tested in nasal sprays with other drugs that are absorbed too poorly or slowly on their own. With these new formulations, doctors and patients have more treatment choices and can select the best option.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ExcipientsPharmaceutical PreparationsAdministration, IntranasalCentral Nervous SystemHumansMucous MembraneUnited States

Substanzen

ExcipientsPharmaceutical Preparations

Autor:innen und Institutionen

  • Neurelis, Inc., San Diego, CA, USA. arabinowicz@neurelis.com.
  • Neurelis, Inc., San Diego, CA, USA.

Förderung

  • Neurelis, Inc.

Zitieren

APA

Rabinowicz, A. L., Carrazana, E., & Maggio, E. T. (2021). Improvement of Intranasal Drug Delivery with Intravail® Alkylsaccharide Excipient as a Mucosal Absorption Enhancer Aiding in the Treatment of Conditions of the Central Nervous System. Drugs in R&D, 21(4), 361-369. https://doi.org/10.1007/s40268-021-00360-5

Vancouver

Rabinowicz AL, Carrazana E, Maggio ET. Improvement of Intranasal Drug Delivery with Intravail® Alkylsaccharide Excipient as a Mucosal Absorption Enhancer Aiding in the Treatment of Conditions of the Central Nervous System. Drugs in R&D. 2021;21(4):361-369. doi:10.1007/s40268-021-00360-5

BibTeX
@article{Rabinowicz2021,
  author = {Rabinowicz, Adrian L and Carrazana, Enrique and Maggio, Edward T},
  title = {Improvement of Intranasal Drug Delivery with Intravail® Alkylsaccharide Excipient as a Mucosal Absorption Enhancer Aiding in the Treatment of Conditions of the Central Nervous System},
  journal = {Drugs in R&D},
  year = {2021},
  volume = {21},
  number = {4},
  pages = {361--369},
  doi = {10.1007/s40268-021-00360-5}
}
Kostenlos starten →